title: Infliximab enhances the therapeutic effectiveness of octreotide on acute necrotizing pancreatitis in rat model.
abstract: OBJECTIVE
  To investigate the synergistic activity of infliximab to the therapeutic effectiveness of octreotide in a rat model of acute necrotizing pancreatitis (ANP).
  
  
  METHODS
  Forty Sprague-Dawley rats were randomly divided into sham-operated group (SO), ANP group (ANP), octreotide group (OG), infliximab group (IG), and combination group (CG) (n = 8 in each group). The ANP model was induced by biliopancreatic duct injection with 4.5% of sodium taurocholate solution. Rats of the OG, IG, and CG were given a tail vein injection of octreotide (10 μg/kg), infliximab (8 mg/kg), and infliximab (8 mg/kg), respectively, combined with octreotide (10 μg/kg) at 6 hours after modeling. All rats in each group were killed at 24 hours after modeling. Serum biochemical indicator and partial pressure of arterial oxygen/fraction of inspired oxygen (PaO2/FiO2) of rats were determined. Pathological severity score of organs were evaluated.
  
  
  RESULTS
  The serum biochemical indicator and organs' pathology score of OG , IG, and CG were obviously lower than those in the ANP group, and those in the CG were the lowest (P < 0.05). The PaO2/FiO2 levels in the OG, IG, and CG were significantly higher than that in the ANP group (P < 0.05).
  
  
  CONCLUSIONS
  Infliximab could significantly lower the serum biochemical indicator, improve organs' function, and enhance the therapeutic effectiveness of octreotide on ANP.
authors.affiliation: Department of Gastroenterology, Guangzhou Nan Sha Center Hospital, Guangzhou, Guangdong Province, China.
authors.forename: Yao-Xing
authors.initials: YX
authors.lastname: Huang
authors.forename: Wei-Dong
authors.initials: WD
authors.lastname: Li
authors.forename: Lin
authors.initials: L
authors.lastname: Jia
authors.forename: Jia-Hua
authors.initials: JH
authors.lastname: Qiu
authors.forename: Shu-Man
authors.initials: SM
authors.lastname: Jiang
authors.forename: Ya
authors.initials: Y
authors.lastname: Ou
authors.forename: Hong
authors.initials: H
authors.lastname: Du
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology*; D015415:Biomarkers / Q000097:blood; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D000069285:Infliximab; D007275:Injections, Intravenous; D017093:Liver Failure / Q000209:etiology / Q000517:prevention & control; D009102:Multiple Organ Failure / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D015282:Octreotide / Q000008:administration & dosage / Q000494:pharmacology*; D019283:Pancreatitis, Acute Necrotizing / Q000097:blood / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D020011:Protective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D051437:Renal Insufficiency / Q000209:etiology / Q000517:prevention & control; D012131:Respiratory Insufficiency / Q000209:etiology / Q000517:prevention & control; D012720:Severity of Illness Index; D013656:Taurocholic Acid; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D015415:Biomarkers; D020011:Protective Agents; D013656:Taurocholic Acid; D000069285:Infliximab; D015282:Octreotide